From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma.
chromaffin system
machine learning
pheochromocytoma
predictive score
recurrence prediction
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
03 Jun 2022
03 Jun 2022
Historique:
received:
09
04
2022
revised:
03
05
2022
accepted:
30
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
A reliable prediction of the recurrence risk of pheochromocytoma after radical surgery would be a key element for the tailoring/personalization of post-surgical follow-up. Recently, our group developed a multivariable continuous model that quantifies this risk based on genetic, histopathological, and clinical data. The aim of the present study was to simplify this tool to a discrete score for easier clinical use. Data from our previous study were retrieved, which encompassed 177 radically operated pheochromocytoma patients; supervised regression and machine-learning techniques were used for score development. After Cox regression, the variables independently associated with recurrence were tumor size, positive genetic testing, age, and PASS. In order to derive a simpler scoring system, continuous variables were dichotomized, using > 50 mm for tumor size, ≤ 35 years for age, and ≥ 3 for PASS as cut-points. A novel prognostic score was created on an 8-point scale by assigning 1 point for tumor size > 50 mm, 3 points for positive genetic testing, 1 point for age ≤ 35 years, and 3 points for PASS ≥ 3; its predictive performance, as assessed using Somers’ D, was equal to 0.577 and was significantly higher than the performance of any of the four dichotomized predictors alone. In conclusion, this simple scoring system may be of value as an easy-to-use tool to stratify recurrence risk and tailor post-surgical follow-up in radically operated pheochromocytoma patients.
Identifiants
pubmed: 35740332
pii: biomedicines10061310
doi: 10.3390/biomedicines10061310
pmc: PMC9219670
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Virchows Arch. 2019 Jun;474(6):721-734
pubmed: 30868297
J Intern Med. 2016 Dec;280(6):559-573
pubmed: 27165774
Eur J Endocrinol. 2016 Oct;175(4):R135-45
pubmed: 27080352
Hypertens Res. 2020 Jun;43(6):500-510
pubmed: 31586159
Horm Metab Res. 2012 May;44(5):385-9
pubmed: 22351478
Eur J Endocrinol. 2002 Jul;147(1):85-94
pubmed: 12088924
Surgery. 2014 Dec;156(6):1523-7; discussion 1527-8
pubmed: 25456947
Endocr Relat Cancer. 2014 May 06;21(3):405-14
pubmed: 24521857
Clin Endocrinol (Oxf). 2017 Nov;87(5):440-450
pubmed: 28746746
Eur J Endocrinol. 2022 Feb 15;186(3):399-406
pubmed: 35363157
J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6
pubmed: 15644401
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2367-2374
pubmed: 30715419
Eur J Cancer. 2012 Jul;48(11):1739-49
pubmed: 22036874
Eur J Clin Invest. 2011 Oct;41(10):1121-8
pubmed: 21692797
Surgery. 2018 Sep;164(3):511-517
pubmed: 29929757
PLoS One. 2017 Nov 8;12(11):e0187398
pubmed: 29117221
J Clin Endocrinol Metab. 2011 Mar;96(3):717-25
pubmed: 21190975
J Intern Med. 2009 Jul;266(1):19-42
pubmed: 19522823
Endocr Connect. 2016 Nov;5(6):89-97
pubmed: 27852633
Hypertens Res. 2020 Nov;43(11):1141-1151
pubmed: 32778780
Am J Surg Pathol. 2002 May;26(5):551-66
pubmed: 11979086
Eur J Endocrinol. 2016 May;174(5):G1-G10
pubmed: 27048283
Korean J Urol. 2011 Apr;52(4):241-6
pubmed: 21556209
J Intern Med. 2005 Jul;258(1):55-66
pubmed: 15953133
Curr Opin Endocrinol Diabetes Obes. 2019 Jun;26(3):146-154
pubmed: 30893083
J Urol. 2011 May;185(5):1583-90
pubmed: 21419457
PLoS One. 2016 Dec 16;11(12):e0168413
pubmed: 27992508
Nat Rev Endocrinol. 2015 Feb;11(2):101-11
pubmed: 25385035
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Psychol Methods. 2002 Mar;7(1):19-40
pubmed: 11928888